Claremon
David Claremon, Maple Glen, PA US
Patent application number | Description | Published |
---|---|---|
20100130471 | Renin Inhibitors - Described are compounds which bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof. | 05-27-2010 |
20100179109 | RENIN INHIBITORS - Disclosed are compounds of Formula (I) wherein the R, R | 07-15-2010 |
20100280005 | Renin Inhibitors - Disclosed are compounds of Formula I, wherein the R, R | 11-04-2010 |
20100317697 | Renin Inhibitors - Disclosed are compounds having the formula (I): wherein the R | 12-16-2010 |
David A. Claremon, Maple Glenn, PA US
Patent application number | Description | Published |
---|---|---|
20100197675 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 - This invention relates to novel compounds of the Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell. | 08-05-2010 |
20110098320 | Lactam Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 - This invention relates to novel compounds of the Formula (I), (I*), (Ia), (Ib), (Ic), (Id), (Ie), (If), (If*), (Ig), (Ih), (Ij), (Ik), (ll1-3), (Im1-3), (In1-3), (lo1-2), (Ip1-9), (Iq1-9), (Ir1-9) and (Is1-3) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell. | 04-28-2011 |
David A. Claremon, Mple Glen, PA US
Patent application number | Description | Published |
---|---|---|
20100184805 | RENIN INHIBITORS - Disclosed are aspartic protease inhibitors represented by the following structural formula: and pharmaceutically acceptable salts thereof. These compounds are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. The present invention is also directed to pharmaceutical compositions comprising a compound described herein or enantiomers, diastereomers, or salts thereof and a pharmaceutically acceptable carrier or excipient. | 07-22-2010 |